Overview

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily. The study is double masked. The patients will receive either treatment for 12 weeks.

Phase:

Phase 4

Details

Lead Sponsor:

Alcon Research

Treatments:

Brinzolamide
Travoprost